DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

Not Applicable

Active, not recruiting

Conditions: Functional Mitral Regurgitation

Interventions: Device: Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)

First Posted Date: 2019-04-29

Last Posted Date: 2024-12-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 19

Registration Number: NCT03929913

Locations: 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
Carilion Medical Center, Roanoke, Virginia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

Structural Heart and Valve Network PROSPECTIVE Registry

Withdrawn

Conditions: Mitral Valve Regurgitation
Heart Failure
Heart Valve Disease
Tricuspid Valve Regurgitation
Aortic Valve Stenosis

First Posted Date: 2019-04-26

Last Posted Date: 2023-01-12

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT03928639

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States

Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome

Phase 1

Completed

Conditions: Skin Fibroblasts
Muscle Weakness
Cancer

Interventions: Dietary Supplement: Nicotinamide Riboside (NR)

First Posted Date: 2018-12-28

Last Posted Date: 2020-12-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1

Registration Number: NCT03789175

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)

Phase 2

Completed

Conditions: Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia (CLL)
Safety and Tolerability
Compare SHINGRIX Vaccine Response Rates

Interventions: Biological: Zoster Vaccine Recombinant, Adjuvanted

First Posted Date: 2018-10-11

Last Posted Date: 2023-08-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 116

Registration Number: NCT03702231

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

Phase 2

Completed

Conditions: Hepatitis
Safety and Tolerability

Interventions: Biological: HEPLISAV-B

First Posted Date: 2018-09-26

Last Posted Date: 2022-02-08

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 78

Registration Number: NCT03685708

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease

Recruiting

Conditions: Sickle Cell
Adenosine Triphosphate Activities
PKLR Variants

First Posted Date: 2018-09-26

Last Posted Date: 2025-04-23

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 800

Registration Number: NCT03685721

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Technical and Translational Development of Cardiovascular Magnetic Resonance (CMR) Imaging

Recruiting

Conditions: Normal and Abnormal Cardiovascular Physiology

First Posted Date: 2018-07-10

Last Posted Date: 2025-05-06

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 5000

Registration Number: NCT03581318

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

Completed

Conditions: Pulmonary Hypertension
Sickle Cell Disease

First Posted Date: 2018-06-28

Last Posted Date: 2021-04-19

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 38

Registration Number: NCT03572036

Locations: 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects

Phase 2

Terminated

Conditions: Heart Failure

Interventions: Dietary Supplement: Nicotinamide Riboside

First Posted Date: 2018-06-21

Last Posted Date: 2020-10-28

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 2

Registration Number: NCT03565328

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States

Vascular Disease Discovery Protocol

Recruiting

Conditions: Genetic Predisposition
Vascular Dysfunction
Genetic Mutations

First Posted Date: 2018-05-29

Last Posted Date: 2025-05-04

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1000

Registration Number: NCT03538639

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy